#ACR25 Clinical Preview by Prof Coates to be applied tomorrow! Early Tx Abstr#1677 First-line TNFi for 12-mth vs step-up = better outcomes at 5-Yr Abstr#2662 Target emulation trial = No differences in hospitalization, death/transplant RTX vs TNFi, ABA, JAK, IL-6i @RheumNow https://t.co/yostJyc5T9

• https://x.com/Yuz6Yusof/status/1983557041424908523/photo/1
• https://x.com/Yuz6Yusof/status/1983557041424908523/photo/1

Click on the link to see my take on implantable vagal nerve stimulation RCT in RA 🎥👇🏼 https://t.co/CZrFKouSqp @RheumNow #ACR25 #ABSTRACT1675

• Wired for Success: Vagal Nerve Therapy in RA | RheumNow

Nice to see a Dietary intervention study in the "Top Abstracts That Will Change My Practice in the Near Future" by L. Coates for Year in Preview Small RCT but fibres significantly improve response to treatment in the MTX treated RA group with a mean reduction of DAS28 of https://t.co/vMeIAK1P5u

• https://x.com/AurelieRheumo/status/1983553385505726631/photo/1

Fukui et al. CorEvitas study. 12076 RA patients. Propensity score matching. Kidney dysfunction (eGFR<60) reduced chance of CDAI remission (HR 0.71) or remission/LDA (HR 0.88) @RheumNow #ACR25 Abstr#2640 https://t.co/uvTjOQlGD7

• https://x.com/RichardPAConway/status/1983549389504135603/photo/1

Autologous CAR-Treg in RA, without any lymphodepletion preRx Early data from ph1, single dose Good initial response, stopped RA Rx, but some rebound Clearly work ongoing but excitement re: - CAR-Treg - RA as target dx - no lymphodepletion @minnakohlermd #ACR25 LB23 @RheumNow https://t.co/azmlFNU02R

• https://x.com/drdavidliew/status/1983540424632615108/photo/1
• https://x.com/drdavidliew/status/1983540424632615108/photo/1
• https://x.com/drdavidliew/status/1983540424632615108/photo/1
• https://x.com/drdavidliew/status/1983540424632615108/photo/1

REGULATE RA SBT-77-701 Engineered Treg cell in Refractory RA population 6patients Safety and tolerability: No DLT, CRS or ICANS Efficacy Reduction >50% in TJC and SJC 67% reduction of DAS-CRP >=2 stained up to wk 24 Impressive in pts for whom it works, yet a couple seem to https://t.co/lQAQABPhg0

• https://x.com/AurelieRheumo/status/1983539634459074639/photo/1
• https://x.com/AurelieRheumo/status/1983539634459074639/photo/1
• https://x.com/AurelieRheumo/status/1983539634459074639/photo/1

Kohler et al. Phase 1 study autologous CAR-Tregs in refractory RA. No lymphodepletion needed! 6 participants. 2 doses, second cohort with higher dose better and more sustained response. No CRS or other toxicities. @RheumNow #ACR25 Abstr#LB023 https://t.co/nWva2R7WOQ

• https://x.com/RichardPAConway/status/1983538058684403805/photo/1

#ACR25 Abstr#LB23 Phase 1 trial in 5 refractory #RA of SBT777101, a novel autologous CAR-Treg (without the need for lymphodepletion) showed promising efficacy and safety signal. No DLT, CRS or ICANS. Looking forward to larger data and in other RMDs @RheumNow https://t.co/YyGMSHjA3z

• https://x.com/Yuz6Yusof/status/1983537965545685387/photo/1
• https://x.com/Yuz6Yusof/status/1983537965545685387/photo/1

Effectiveness of b/tsDMARDs RA pts kidney dysfunction CorEvitas RA registry 9,569 pts Pts low eGFR = older more comorbidities less NSAIDs Reduced eGFR = 30% less likely to achieve remission Persists indeed of GC intake Is it a PK/PD related issue or somehow the reflection of https://t.co/KZuvPVa6eg

• https://x.com/AurelieRheumo/status/1983535872038363477/photo/1

Cellular Biomarkers of Rheumatoid Arthritis https://t.co/mLYZRX9ypm Biomarkers of RA by @jeffsparks Lots of promising biomarkers, we need validation and hopefully translation to clinical practice. @RheumNow #ACR25

• Cellular Biomarkers of Rheumatoid Arthritis

Microbiome signature for prediction of response to MTX in RA: Yay or Nay? Microbiome analysis 60pts, 23 MTX NR BL enrichment in specific species in MTX NR Looking at the graphs though, seems to be driven by a few pts Prediction model doesn't seem to perform greatly Sens 88% https://t.co/1yrSXdE6DG

• https://x.com/AurelieRheumo/status/1983534365045854650/photo/1

Regulate-RA study, first-in-human Phase 1 study data show citrullinated protein (CitP)-targeted CAR-Tregs (SBT777101) are safe and show early efficacy in refractory RA. 67% had ≥50% joint count reduction by Week 4. A novel, non-cytotoxic approach to immune modulation for https://t.co/g153w3XVEK

• https://x.com/synovialjoints/status/1983534285941313978/photo/1

Ph2B RCT of Rosnilimab Tcell depleter (PD-1high Tph/Tfh, Teff) Wk 12 Primary Endpoint met Mean change DAS28-CRP at Wk 12 SC rosnilimab 100mg Q4W -2.06 400mg Q4W -2.12 600mg Q2W -2.06 PBO -1.69 >90% peripheral and synovial depletion pathogenic T cells 28 Wk Safety profile: https://t.co/XyVhJamFdp

• https://x.com/AurelieRheumo/status/1983529880982519845/photo/1
• https://x.com/AurelieRheumo/status/1983529880982519845/photo/1

Not all RA meds are equal for the heart. In >10K older adults w/ RA, advanced therapies lowered MACE risk (HR 0.63) vs csDMARDs, while GCs ↑ risk (HR 1.54) and undertreatment ↑ it 13-fold. Control inflammation, protect the heart. @RheumNow #ACR25 Abstract #2642